FDA accepts Eisai’s BLA for LEQEMBI subcutaneous autoinjector for alzheimer’s disease treatment EP News Bureau Jan 15, 2025 LEQEMBI’s subcutaneous formulation could simplify maintenance therapy for Alzheimer’s patients, offering a 15-second at-home…
Glenmark receives ANDA approval for Dimethyl Fumarate Delayed-Release capsules EP News Bureau Oct 9, 2019 The drug is indicated to treat relapsing forms of multiple sclerosis Glenmark Pharmaceuticals has been granted tentative…
